DelveInsight’s, “Frontotemporal Dementia Pipeline Insight 2025” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Frontotemporal Dementia pipeline landscape. It covers the Frontotemporal Dementia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Frontotemporal Dementia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in the Frontotemporal Dementia Pipeline? Click here to explore the therapies and trials making headlines @ Frontotemporal Dementia Pipeline Outlook Report
Key Takeaways from the Frontotemporal Dementia Pipeline Report
- On 03 September 2025, Azafaros A.G. conducted a phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick type C disease.
- DelveInsight’s Frontotemporal Dementia Pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Frontotemporal Dementia treatment.
- The leading Frontotemporal Dementia Companies such as Alector, GSK, Eli Lilly and Company, Transposon Therapeutics, Passage Bio, AviadoBio, Vesper Bio, Neurimmune Therapeutics, Asceneuron SA and others.
- Promising Frontotemporal Dementia Therapies such as LY3884963, Methylprednisolone, Optional Sirolimus, DNL593, AL001, Vortioxetine, PBFT02, galantamine hydrobromide, and others.
Want to know which companies are leading innovation in Frontotemporal Dementia? Dive into the full pipeline insights @ Frontotemporal Dementia Clinical Trials Assessment
The Frontotemporal Dementia Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Frontotemporal Dementia Pipeline Report also highlights the unmet needs with respect to the development of Frontotemporal Dementia.
Frontotemporal Dementia Overview
Frontotemporal Dementia (FTD) refers to a group related conditions resulting from the progressive degeneration of the frontal and temporal lobes of the brain. These areas of the brain play a significant role in behavior, language and decision-making abilities. FTD is considered a young-onset dementia, occurring between the ages of 45–65 and is the most common dementia in those under 60 years. It displays clinical symptoms that can be mistaken for other dementias or psychiatric disorders. The average time from symptom onset to accurate diagnosis is about 3.6 years. The aggregation of misfolded, dysfunctional proteins in specific brain regions is a common feature across many neurological diseases and acts as a pathologic hallmark.
Frontotemporal Dementia Emerging Drugs Profile
- AL001: Alector/ GSK
Alector Inc. initiated the development of a Sortilin inhibitor AL001 for the treatment of Frontotemporal Dementia. AL001 is a recombinant human anti-human sortilin (SORT1) monoclonal IgG1 developed by Alector in partnership with GSK. It aims to increase the level of progranulin in humans by inhibiting a progranulin degradation mechanism. The antibody received orphan drug designation, fast track designation, and breakthrough designation from the US FDA for the treatment of frontotemporal dementia. In July 2021, GSK and Alector entered into a global collaboration for the development and commercialization of two monoclonal antibodies (AL001 and AL101) designed to elevate progranulin (PGRN) levels. The company is currently investigating AL001 in Phase III clinical trials for FTD with a C9orf72 mutation and granulin mutation.
- TPN-101: Transposon Therapeutics
TPN-101 specifically inhibits the LINE-1 reverse transcriptase that promotes LINE-1 replication. LINE-1 elements are a class of retrotransposable elements that in humans are uniquely capable of replicating and moving to new locations within the genome. When this process becomes dysregulated, LINE-1 reverse transcriptase drives overproduction of LINE-1 DNA, triggering innate immune responses that contribute to neurodegenerative, autoimmune and aging-related disease pathology. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Frontotemporal Dementia.
- AVB-101: AviadoBio
AVB-101 is a potential one-time therapy designed to stop disease progression by delivering a functional copy of the GRN gene to restore appropriate progranulin levels to affected areas of the brain. The drug is delivered using a minimally invasive, stereotactic neurosurgical procedure directly to the part of the brain called the thalamus. The thalamus has extensive connections to other parts of the brain, including the frontal and temporal lobes, which play a critical role in FTD and the symptoms that impact patients and their families. This targeted delivery method aims to safely and effectively cross the blood-brain barrier, delivering targeted treatment directly to the brain to restore progranulin levels in the frontal and temporal cortex where it is needed most, while at the same time minimizing the dose required and thereby limiting any potential systemic exposure. In November 2023, the US Food and Drug Administration (FDA) granted Fast Track designation to AVB-101. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Frontotemporal Dementia.
- PBFT02: Passage Bio
It is a gene therapy product candidate, an AAV1 viral vector to deliver a modified DNA encoding the granulin gene (GRN) to a patient’s cells. The vector will be delivered directly to the cerebrospinal fluid by a single injection to the cisterna magna (ICM injection). The goal of this vector and delivery approach is to provide higher-than-normal levels of the progranulin protein (PGRN) to the CNS to overcome the progranulin deficiency in GRN gene mutation carriers. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Frontotemporal Dementia.
The Frontotemporal Dementia Pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Frontotemporal Dementia with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Frontotemporal Dementia Treatment.
- Frontotemporal Dementia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Frontotemporal Dementia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Frontotemporal Dementia market.
If you’re tracking ongoing Frontotemporal Dementia clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Frontotemporal Dementia Treatment Drugs
Frontotemporal Dementia Companies
Alector, GSK, Eli Lilly and Company, Transposon Therapeutics, Passage Bio, AviadoBio, Vesper Bio, Neurimmune Therapeutics, Asceneuron SA and others.
Frontotemporal Dementia Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Frontotemporal Dementia Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
From emerging drug candidates to competitive intelligence, the Frontotemporal Dementia Pipeline Report covers it all – check it out now @ Frontotemporal Dementia Market Drivers and Barriers, and Future Perspectives
Scope of the Frontotemporal Dementia Pipeline Report
- Coverage- Global
- Frontotemporal Dementia Companies- Alector, GSK, Eli Lilly and Company, Transposon Therapeutics, Passage Bio, AviadoBio, Vesper Bio, Neurimmune Therapeutics, Asceneuron SA and others.
- Frontotemporal Dementia Therapies- LY3884963, Methylprednisolone, Optional Sirolimus, DNL593, AL001, Vortioxetine, PBFT02, galantamine hydrobromide, and others.
- Frontotemporal Dementia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Frontotemporal Dementia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in oncology research – discover what’s next for the Frontotemporal Dementia treatment landscape in this detailed analysis @ Frontotemporal Dementia Emerging Drugs and Major Players
Table of Contents
- Introduction
- Executive Summary
- Frontotemporal Dementia: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Frontotemporal Dementia– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- AL001: Alector/ GSK
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- TPN-101: Transposon Therapeutics
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug name: Company name
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Frontotemporal Dementia Key Companies
- Frontotemporal Dementia Key Products
- Frontotemporal Dementia- Unmet Needs
- Frontotemporal Dementia- Market Drivers and Barriers
- Frontotemporal Dementia- Future Perspectives and Conclusion
- Frontotemporal Dementia Analyst Views
- Frontotemporal Dementia Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/frontotemporal-dementia-pipeline-insight